Open AccessThe impact of ruxolitinib treatment on inflammation‐mediated comorbidities in myelofibrosis and related neoplasms
Author(s) -
Bjørn Mads Emil,
Hasselbalch Hans Carl
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.281
Subject(s) - ruxolitinib , medicine , myelofibrosis , inflammation , oncology , intensive care medicine , bone marrow
Key clinical message The inflammation‐mediated comorbidities in myelofibrosis ( MF ) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK 1‐2 inhibitors in MF ‐patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation‐mediated comorbidities.